Given the role of SFKs in the development and progression of Ph+ ALL and CML and in BCR-ABL–independent imatinib resistance, dual inhibition of BCR-ABL and SFK will likely prove a more effective treatment strategy. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.